Profile: Spectral Medical Inc. is committed to decreasing the high mortality rates caused by sepsis. By combining complementary diagnostics and therapeutics, or theranostics, Spectral's vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.

Spectral's EAAT Endotoxin Activity Assay is the only FDA cleared, CE marked rapid diagnostic for endotoxemia. Endotoxin is an early objective marker for severity of sepsis that may not be identified with traditional clinical signs. Spectral holds the exclusive rights for Toraymyxin in the U.S. and Canada, and is currently conducting a Phase III clinical trial for severe sepsis and septic shock.Toraymyxin is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream. Spectral provides high quality, high performance biochemicals for research and commercial products. Possessing a long onboard shelf life, Spectral's single-chain Troponin I-C polypeptides, and other reagent products, have been recognized by the market as a premier reagent for large instrument calibration and control.

FDA Registration Number: 9617857
US Agent: Olga Pavlova / Spectral Diagnostics Us, Inc. ( C/o Amarex, Llc)
Phone: +1-(240)-235-6857  Fax: +1-(301)-528-2300  E-Mail: